North America Pharmaceutical Contract Manufacturing Market - By Type , Country, Trends, Forecasts - 2017 - 2022

  • ID: 4389682
  • Report
  • Region: North America, United States
  • 90 pages
  • Mordor Intelligence
1 of 4
Contract Manufacturing refers to the outsourcing of manufacturing of the products to Third party vendor. These Pharmaceutical Contract Manufacturers would be given the chemical formulation of the drug from the Pharmaceutical company and then prepare/manufacture in their location. Contract Manufacturing market is growing significantly since the pharmaceutical companies are focusing more on R&D of the drugs instead of manufacturing the formulated drug to stay competitive in the market. This is driving the Pharmaceutical Contract Manufacturing Market.

The North America Pharmaceutical Contract Manufacturing market is estimated to grow at a compound annual growth rate of 6.80% during the period 2017 - 2022. Active Pharmaceutical Ingredient (API) holds the highest market share while Final dosage form is estimated to be the top growing segment during the forecasted period. The companies in the upstream industry are undergoing restructuring so as to focus more on R&D and added to this; stringent regulations on the Pharmaceutical industry are compelling the companies to outsource the manufacturing of the drugs.

Pharmaceutical companies are going for less number of vendors to take volume advantage and at the same time reduce logistics costs.
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Study Deliverables
1.2 Key Findings of the Study
1.3 Market Definition
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Current Market Trends
4.2 Drivers
4.2.1 Growing Innovative drugs
4.2.2 Increasing Investments in R&D
4.3 Restraints
4.3.1 In-house packaging
4.3.2 Capacity Utilization Issues Affecting the Profitability of CMOs
4.3.3 Increasing Lead Time & Logistics Costs
4.4 Market Opportunities
4.4.1 Huge Demand for Next Generation Biological Surgeries
4.5 Porters Five Force Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products and Services
4.5.5 Intensity of Competitive Rivalry
4.6 Industry Value Chain Analysis
4.7 Industry Policies
5. Technology Snapshot
5.1 Dosage Formulation Technologies
5.1.1 Abuse Deterrent Formulation Technology
5.1.2 Lipid Marti-particulate Technology
5.1.3 Dry powder Inhalation Technology
5.1.4 Force Control Agent Technology
5.1.5 High Potency Drug Formulation Technology
5.1.6 Fluidized Bed Coating Technology
5.1.7 Form EZE Technology
5.2 Dosage Forms by Route of Administration
5.2.1 Oral
5.2.2 Topical
5.2.3 Parenteral
5.2.4 Rectal
5.2.5 Vaginal
5.2.6 Inhaled
5.2.7 Ophthalmic
5.2.8 OTIC
6. North America Pharmaceutical Contract Manufacturing Market Segmentation - By Type
6.1 Active Pharmaceutical Ingredient (API) Manufacturing
6.2 Finished Dosage Formulation (FDF) Development and Manufacturing
6.2.1 Solid Dosage Formulation
6.2.2 Liquid Dose/Semi-Solid Formulation
6.2.3 Injectable Dose Formulation
6.3 Secondary Market
7. Pharma CMO Market -Segmented by geography
7.1 North America
7.1.1 United States
7.1.2 Canada
8. North America Pharmaceutical Contract Manufacturing Vendor Market Share
9. Competitive Intelligence - Company Profiles
9.1 Catalent Inc
9.2 Recipharm AB
9.3 Aptiut LLC
9.4 Patheon Inc
9.5 Daito Pharmaceutical
9.6 AbbVie Inc
9.7 Pfizer Centre Source
9.8 Aenova (Haupt) Group
9.9 Famar Inc
9.10 Baxter Bio Pharma Solutions
9.11 Lonza Group
9.12 Contract Pharmaceuticals Limited
9.13 Confab Inc
10. Investment Analysis
10.1 Recent Mergers & Acquisitions
10.2 Investment Scenario and Opportunities
11. Future of Pharmaceutical Contract Manufacturing Market
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll